Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.49 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22493232 | 0.83 | PDE10A (0.47) | CYSLTR1CYSLTR2CYP1A2NCF1PDE10A | |
| SCHEMBL2924050 | 0.79 | NCF1 (0.53) | CYSLTR1CYSLTR2KDM1AMAOAMAOB | |
| SCHEMBL24943587 | 0.79 | HDAC1 (0.55) | CYSLTR1CYSLTR2KDM1AMAOAMAOB | |
| SCHEMBL13959075 | 0.78 | PDE10A (0.42) | CYSLTR1CYSLTR2CYP1A2HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL7830119 | 0.78 | NCF1 (0.52) | CYSLTR1CYSLTR2KDM1AMAOAMAOB | |
| SCHEMBL13959082 | 0.77 | HDAC1 (0.49) | CYP1A2HDAC1HDAC2PDE10A | |
| SCHEMBL13959081 | 0.77 | HDAC1 (0.49) | CYSLTR1CYSLTR2HDAC1HDAC2KDM4E | |
| SCHEMBL1039381 | 0.76 | KDM1A (0.48) | CYSLTR1CYSLTR2KDM1AMAOAMAOB | |
| SCHEMBL31536348 | 0.76 | HDAC1 (0.56) | CYSLTR1CYP1A2HDAC1HDAC2HPGD | |
| SCHEMBL13959104 | 0.76 | TERT (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2984094-B1 | PROCESS FOR THE DIASTEREOSELECTIVE PREPARATION OF RUTHENIUM COMPLEXES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-05-13 | — | — | EP | disclosed |
| US-9303054-B2 | Process for the diastereoselective preparation of ruthenium complexes | SYNGENTA PARTICIPATIONS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| US-9303054-B2 | Process for the diastereoselective preparation of ruthenium complexes | SYNGENTA PARTICIPATIONS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| US-20160046658-A1 | PROCESS FOR THE DIASTEREOSELECTIVE PREPARATION OF RUTHENIUM COMPLEXES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-02-18 | — | — | US | disclosed |
| US-20160046658-A1 | PROCESS FOR THE DIASTEREOSELECTIVE PREPARATION OF RUTHENIUM COMPLEXES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-02-18 | — | — | US | disclosed |
| WO-2014166777-A1 | PROCESS FOR THE DIASTEREOSELECTIVE PREPARATION OF RUTHENIUM COMPLEXES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | WO | disclosed |
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | HILL JASON | 2009-01-08 | — | — | US | disclosed |
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | HILL JASON | 2009-01-08 | — | — | US | disclosed |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CUBIST PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CUBIST PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-7408025-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | CYSLTR1 484/4885CYSLTR2 527/4885KDM1A 4378/4885 |
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | CYSLTR1 484/4885CYSLTR2 527/4885KDM1A 4378/4885 |
| US-20160046658-A1 | PROCESS FOR THE DIASTEREOSELECTIVE PREPARATION OF RUTHENIUM COMPLEXES | C1R, C5, C1S | CYSLTR1 453/4885CYSLTR2 386/4885KDM1A 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.